Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biomarin
Biomarin
Sarepta’s competitor on Duchenne drug could get a two-month head start on sales
Bizjournals.com
Wed, 10/14/15 - 02:23 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Biomarin
eteplirsen
drisapersen
Sarepta Therapeutics vs. BioMarin Pharmaceutical: Which Company Will Win the DMD Race?
Motley Fool
Tue, 10/6/15 - 07:13 pm
Sarepta Therapeutics
Biomarin
Duchenne Muscular Dystrophy
eteplirsen
drisapersen
What It's Like To Have Dinner With BioMarin Executives
Yahoo/Benzinga
Wed, 09/16/15 - 06:12 pm
Biomarin
Sarepta snags priority review status to keep pace with BioMarin in DMD race
Fierce Biotech
Wed, 08/26/15 - 09:28 am
Sarepta Therapeutics
priority review
Duchenne Muscular Dystrophy
FDA
eteplirsen
drisapersen
Biomarin
Why BioMarin hawked a phase III cancer drug to Medivation for $570M
BioPharma Dive
Wed, 08/26/15 - 08:47 am
Biomarin
Medivation
BMN 673
Sarepta, Biomarin vie for DMD approval, priority review voucher
BioPharma Dive
Mon, 08/24/15 - 11:47 am
Sarepta
Biomarin
Duchenne Muscular Dystrophy
FDA
priority review
review vouchers
BioMarin sells its PhIII cancer drug to Medivation for $570M
Fierce Biotech
Mon, 08/24/15 - 11:22 am
Biomarin
Medivation
talazoparib
breast cancer
BRCA1
BRCA2
BioMarin's Big Bet on Muscular Dystrophy Is Already Paying Off
Motley Fool
Sat, 08/22/15 - 09:01 am
Biomarin
Duchenne Muscular Dystrophy
drisapersen
3 Biotech Stocks That Could Be Buyout Targetst
Motley Fool
Fri, 08/21/15 - 09:46 am
Intrexon
Ziopharm
Bluebird Bio
Biomarin
The 5 Most Expensive Drugs in the World in 2015
Motley Fool
Sun, 08/16/15 - 10:32 am
drug pricing
Glybera
Soliris
Naglazyme
Vimizim
Elaprase
Shire
Biomarin
Alexion
uniQure
BioMarin outlines its R&D game plan as Duchenne MD decision nears
Fierce Biotech
Tue, 08/4/15 - 05:51 pm
Biomarin
R&D
Duchenne Muscular Dystrophy
drisapersen
3 Biotech Stocks to Buy With Huge Catalysts Coming Soon
24/7 Wall St
Mon, 08/3/15 - 12:17 pm
Biomarin
drisapersen
Cempra
Solithromycin
antibiotics
Tetraphase Pharmaceuticals
Eravacycline
FDA Closing In on November Expert Panel Date for BioMarin, Sarepta Drugs
TheStreet.com
Mon, 07/20/15 - 02:37 pm
FDA
Biomarin
advisory panels
eteplirsen
Sarepta Therapeutics
drisapersen
Duchenne Muscular Dystrophy
BioMarin shines as dwarfism drug boosts growth in children
Fierce Biotech
Thu, 06/18/15 - 10:28 am
Biomarin
dwarfism
BMN-111
FDA finally responds to demand for Duchenne Muscular Dystrophy guidance
BioPharma Dive
Wed, 06/10/15 - 10:58 am
FDA
Duchenne Muscular Dystrophy
Saretpa
PTC Therapeutics
Pfizer
Biomarin
Upcoming Events: A Dosing Decision For BioMarin, Plus Roche To Get Alzheimer's Data
Seeking Alpha
Mon, 05/25/15 - 12:41 pm
Biomarin
Roche
Alzheimer's disease
RG1577
These biotech names are ripe for mergers: Analysts
CNBC
Sun, 05/10/15 - 02:04 pm
Biomarin
Sanofi
Shire
Gilead Sciences
Vertex Pharmaceuticals
Ariad Pharmaceuticals
Why These 4 Biotech Stocks Could Be the Next Buyout Targets
24/7 Wall St
Thu, 05/7/15 - 09:23 am
biotech
M&A
Biomarin
Bluebird Bio
Incyte
Vertex Pharmaceuticals
Why BioMarin’s New Drug Application is Good News for Sarepta Therapuetics
Fierce Pharma Marketing
Wed, 05/6/15 - 11:44 am
Biomarin
Sarepta Therapeutics
drisapersen
Duchenne Muscular Dystrophy
4 Big Biopharma Deals We Might See In 2015
Seeking Alpha
Fri, 04/17/15 - 08:42 am
AbbVie
AstraZeneca
Biomarin
Bristol-Myers Squibb
Celgene
Gilead Sciences
GSK
Hospira
Jazz Pharmaceuticals
Merck
Seattle Genetics
Shire
Pages
« first
‹ previous
…
5
6
7
8
9
10
11
12
13
…
next ›
last »